Canadian health authorities approved Amylyx Pharmaceuticals Inc.’s new drug for amyotrophic lateral sclerosis, the progressive neurodegenerative disease that robs patients of their ability to move and speak.
It is the first Canadian approval since 2018 for a new drug treating the fatal condition, which is also known as Lou Gehrig’s disease.
